ORIC Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
ORIC Pharmaceuticals's earnings have been declining at an average annual rate of -22.9%, while the Biotechs industry saw earnings growing at 12.7% annually.
Key information
-22.9%
Earnings growth rate
51.8%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | n/a |
Return on equity | -44.9% |
Net Margin | n/a |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
ORIC Pharmaceuticals: Mid-2024 Prostate Cancer Program Update Could Lead To Gains
Mar 13We're Not Very Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Rate
Jan 18We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth
Sep 27ORIC Pharmaceuticals (NASDAQ:ORIC) Is In A Good Position To Deliver On Growth Plans
Jun 14Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth
Jan 24ORIC Pharmaceuticals: Poster Child For The Current Downturn In Biotech
Oct 14Is ORIC Pharmaceuticals (NASDAQ:ORIC) In A Good Position To Deliver On Growth Plans?
Oct 08ORIC Pharmaceuticals GAAP EPS of -$0.51 beats by $0.09
Aug 11ORIC Pharmaceuticals (NASDAQ:ORIC) Is In A Good Position To Deliver On Growth Plans
Jun 24We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely
Mar 08We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth
Nov 23We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth
Aug 05ORIC Pharmaceuticals EPS beats by $0.04
May 06Here's Why We're Not Too Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Situation
Apr 16We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely
Jan 01Oric Pharma starts expansion phase of mid-stage solid tumor study with ORIC-101
Dec 21Oric Pharma prices stock offering at $23
Nov 13Revenue & Expenses BreakdownBeta
How ORIC Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -101 | 26 | 85 |
30 Sep 23 | 0 | -93 | 24 | 77 |
30 Jun 23 | 0 | -93 | 24 | 69 |
31 Mar 23 | 0 | -90 | 25 | 64 |
31 Dec 22 | 0 | -89 | 25 | 62 |
30 Sep 22 | 0 | -91 | 25 | 62 |
30 Jun 22 | 0 | -85 | 25 | 60 |
31 Mar 22 | 0 | -85 | 24 | 62 |
31 Dec 21 | 0 | -79 | 22 | 57 |
30 Sep 21 | 0 | -84 | 20 | 52 |
30 Jun 21 | 0 | -91 | 18 | 48 |
31 Mar 21 | 0 | -81 | 16 | 40 |
31 Dec 20 | 0 | -74 | 13 | 36 |
30 Sep 20 | 0 | -54 | 11 | 31 |
30 Jun 20 | 0 | -35 | 9 | 28 |
31 Mar 20 | 0 | -30 | 7 | 25 |
31 Dec 19 | 0 | -27 | 6 | 23 |
31 Dec 18 | 0 | -21 | 3 | 19 |
Quality Earnings: ORIC is currently unprofitable.
Growing Profit Margin: ORIC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ORIC is unprofitable, and losses have increased over the past 5 years at a rate of 22.9% per year.
Accelerating Growth: Unable to compare ORIC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ORIC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: ORIC has a negative Return on Equity (-44.94%), as it is currently unprofitable.